Immune cell proportions correlate with clinicogenomic features and ex vivo drug responses in acute myeloid leukemia

Kyle A. Romine, Daniel Bottomly, William Yashar, Nicola Long, Matthew Viehdorfer, Shannon K. McWeeney, Jeffrey W. Tyner

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Introduction: The implementation of small-molecule and immunotherapies in acute myeloid leukemia (AML) has been challenging due to genetic and epigenetic variability amongst patients. There are many potential mechanisms by which immune cells could influence small-molecule or immunotherapy responses, yet, this area remains understudied. Methods: Here we performed cell type enrichment analysis from over 560 AML patient bone marrow and peripheral blood samples from the Beat AML dataset to describe the functional immune landscape of AML. Results: We identify multiple cell types that significantly correlate with AML clinical and genetic features, and we also observe significant correlations of immune cell proportions with ex vivo small-molecule and immunotherapy responses. Additionally, we generated a signature of terminally exhausted T cells (Tex) and identified AML with high monocytic proportions as strongly correlating with increased proportions of these immunosuppressive T cells. Discussion: Our work, which is accessible through a new “Cell Type” module in our visualization platform (Vizome; http://vizome.org/), can be leveraged to investigate potential contributions of different immune cells on many facets of the biology of AML.

Original languageEnglish (US)
Article number1192829
JournalFrontiers in Oncology
Volume13
DOIs
StatePublished - 2023

Keywords

  • AML – acute myeloid leukemia
  • RNAseq analysis
  • checkpoint inhibition therapy
  • functional genomic data
  • immune therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Immune cell proportions correlate with clinicogenomic features and ex vivo drug responses in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this